🚨 New NEJM Study Alert! 🩺💔

Do beta-blockers still help after a heart attack if there’s no heart failure? 🤔

In the BETAMI–DANBLOCK trial (🇩🇰+🇳🇴, n=5574), beta-blocker therapy in post-MI patients with preserved or mildly reduced LVEF (≥40%) modestly reduced the composite outcome of death or major cardiovascular events 🧠📉

📌 Primary endpoint: 14.2% (BB) vs. 16.3% (no BB) → HR 0.85, p=0.03

💡 Especially lowered risk of recurrent MI (HR 0.73)

🧠 Even in the era of PCI, DAPT & statins, beta-blockers may still bring benefit — especially in patients with mildly reduced LVEF (40–49%) 🫀

🔗 [Add your slide link or DOI here]

#Cardiology #NEJM #HeartAttack #BetaBlockers #PostMI #EvidenceBasedMedicine #LVEF #PrecisionMedicine #ClinicalTrials

💥 New NEJM Trial Alert!

A modest 0.3 mmol/L rise in potassium (via MRA, KCl, or diet) significantly reduced arrhythmias, ICD shocks, and hospitalizations in high-risk ICD patients ⚡🫀

📉 HR 0.76 for the composite endpoint

🔢 NNT = 12.3 over 3.3 years

🍌 Safe, scalable, and globally relevant

👉 Time to rethink “normal” K⁺ levels in cardiology!

#Cardiology #Electrophysiology #NEJM #ICD #Potassium #POTCAST

🚨 New RCT Alert from the NEJM!

Can an old 💊 make a comeback in modern 💓 failure care?

📌 The DIGIT-HF trial showed that digitoxin, a cardiac glycoside with hepatic clearance, reduced the combined endpoint of all-cause death or HF hospitalization in HFrEF patients on contemporary guideline-directed therapy — including ARNI, beta-blockers, MRAs & SGLT2i.

🩺 HR = 0.82; p = 0.03 📉

👩‍⚕️ Safe in CKD, consistent benefit in women.

⚠️ Serious AEs slightly higher (4.7% vs 2.8%)

📥 NNT = 22.

💡Is it time to reconsider digitoxin in advanced HFrEF?

#CardioTwitter #HFrEF #HeartFailure #Digitoxin #NEJM #Cardiology #SGLT2i #GuidelineTherapy

🚨 Calcific Aortic Valve Stenosis (CAVS): Beyond Wear and Tear 🫀🪨

Once thought to be “degenerative,” CAVS is now recognized as an active disease driven by oxidative stress ⚡, inflammation 🔥, and lipoprotein(a) 🧬. Despite its growing global burden, no drug therapy slows its progression.

🩺 Current management: Surgical (SAVR) or Transcatheter (TAVR) valve replacement.

💊 Emerging hope: PCSK9 inhibitors, Lp(a) lowering agents, SGLT2 inhibitors, soluble guanylate cyclase activators, and anti-inflammatory strategies.

📊 Modern tools: Aortic valve calcification on CT, PET imaging for microcalcification, and strain imaging for early detection.

🔑 Takeaway: CAVS is preventable in theory, but not yet in practice. Novel therapeutics may finally reshape its natural history.

#Cardiology #HeartValve #PrecisionMedicine #AorticStenosis

🚨 New in The Lancet (2025) 🚨

A mega meta-analysis of 484 RCTs (104K+ participants) offers a game-changing approach to hypertension management! 💊📉

Instead of guessing how much BP will drop, now you can predict it—by drug, dose, and combo! 🎯

Like statins for LDL, this study introduces low-, moderate-, and high-intensity BP regimens based on expected mmHg reductions. 💡

Use the free calculator 🔢 at www.bpmodel.org and rethink the “measure-treat-measure” loop.

🩺 Data-driven. Predictable. Efficient. Just what primary care and cardiology need.

#Hypertension #BloodPressure #Cardiology #MetaAnalysis #PrecisionMedicine #Lancet2025 #BPcalculator #MedTwitter #InternalMedicine #DigitalHealth 💻📊🧬

🧒❤️ Partial Heart Transplant: A Growing Solution for Growing Hearts! 🌱🔬

🚨 Pediatric patients with congenital heart valve disease often face multiple surgeries due to non-living valve grafts that don’t grow. This landmark study from @DukeHealth shows how living valves via partial heart transplant can change the game.

📊 In 19 patients (median age: 97 days), transplanted valves showed true annular and leaflet growth — with low immunosuppression and no valve-related reinterventions. The innovative “Living Ross” approach offers a promising path for long-term durability.

🧬 Organ stewardship, reduced surgeries, and biologic adaptation — the future is here.

🔗 Read the full JAMA study

#PediatricCardiology #HeartTransplant #InnovationInSurgery #LivingRoss #JAMA #CardiacSurgery #ValveReplacement #CongenitalHeartDisease #PartialHeartTransplant #PrecisionMedicine 🫀📈

🐖🫁 World First: Pig Lung Transplanted into Human 🧬🌍

In a groundbreaking step for xenotransplantation, a team in China successfully transplanted a genetically modified pig lung into a brain-dead human recipient. The lung functioned for 216 hours without hyperacute rejection, offering hope to thousands on organ waitlists.

🔬 Key breakthroughs:

• 6-gene-edited donor pig

• No Porcine Endogenous Retrovirus (PERV-C) detected 🦠

• Controlled immune response 🛡️

• PGD observed but stabilized 💉

📖 Published in Nature Medicine: https://doi.org/10.1038/s41591-025-03861-x

👏 A monumental leap toward clinical trials and saving lives.

#Xenotransplantation #LungTransplant #OrganDonation #Immunology #PrecisionMedicine #NatureMedicine #TranslationalScience 🚀

🧬 Pre-Heart Failure? Let Age Speak! 👵👴

New study in JACC compares fixed vs age-adjusted NT-proBNP cutoffs for defining pre–heart failure (Pre-HF) in over 22,000 adults across ARIC, MESA, and CHS cohorts.

📉 Key Insight: Age-adjusted cutoffs reduce overdiagnosis in older adults 🧓 and improve risk prediction for heart failure hospitalization 🏥.

📊 With better C-statistics, NRI, IDI, and a lower number needed to screen, the age-specific approach proves more precise—especially in those ≥75 years.

⚖️ One-size-fits-all doesn’t fit the aging heart. Time to tailor biomarkers by age! ⏳❤️

#HeartFailure #NTproBNP #Cardiology #PrecisionMedicine #Biomarkers #PreventiveCardiology #JACC #PreHF #RiskStratification #PopulationHealth

🚨 Game-Changer in Lung Cancer! 🫁💉

The 5-year results from CheckMate 816 are in! Neoadjuvant nivolumab + chemotherapy significantly improved survival in resectable NSCLC 🎯

✅ 65.4% 5-year OS vs. 55.0% with chemo alone

🧬 pCR = 95.3% survival

📉 ctDNA clearance = better outcomes

⚖️ Time to rethink neoadjuvant strategies

📚 Read in NEJM: A landmark in thoracic oncology!

#LungCancer #Immunotherapy #NSCLC #Nivolumab #Oncology #CancerResearch #PrecisionMedicine

🚨 New insights from EHJ 2025! 🚨

In statin-treated patients undergoing PCI, inflammation (hsCRP ≥2 mg/L)—not elevated LDL-C—was the strongest predictor of MACE at 1 year 🔥🧪

📊 Bay et al. show that residual inflammatory risk carries a 1.8x higher hazard for adverse events, while LDL-C alone showed no independent risk 💥

🧠 Time to shift focus beyond lipids: consider anti-inflammatory therapies, remnant cholesterol, and Lp(a) in risk stratification 🩺🎯

📖 Read the study ➡️ https://doi.org/10.1093/eurheartj/ehaf196

#Cardiology #Inflammation #ResidualRisk #PCI #Statins #PrecisionMedicine